Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a... ORIGINAL ARTICLE Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer Janessa J. Laskin, MD,* Garth Nicholas, MD,† Christopher Lee, MD,‡ Barbara Gitlitz, MD,§ Mark Vincent, MD, Yvon Cormier, MD,¶ Joe Stephenson, MD,# Yee Ung, MD,** Rachel Sanborn, MD,†† Bryn Pressnail, MD,‡‡ Francis Nugent, MD,§§ John Nemunaitis, MD, Martin E. Gleave, MD,¶¶ Nevin Murray, MD,## and Desiree Hao, MD*** decreased serum CLU levels in 95% of patients evaluated. Patients who Purpose: Clusterin (CLU), an antiapoptotic, stress-associated pro- achieved a minimum median CLU level for the population of 38 tein, confers resistance to therapy when overexpressed. This trial g/ml during treatment had a median survival of 27.1 compared with tested custirsen (OGX-011), an inhibitor of CLU protein production, 16.1 months for patients who did not (p  0.02). combined with gemcitabine/platinum in patients with advanced Conclusion: Based on the above results, a randomized phase 3 trial non-small cell lung cancer (NSCLC). to evaluate the survival benefit of custirsen in patients with NSCLC Patients and Methods: This was a single-arm, multicenter, phase is warranted. I/II study in chemotherapy-naive stage IIIB/IV NSCLC. Custirsen http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

Hao, Desiree
Journal of Thoracic Oncology , Volume 7 (3) – Mar 1, 2012
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/phase-i-sol-ii-trial-of-custirsen-ogx-011-an-inhibitor-of-clusterin-in-zZUDesxsud

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31823f459c
pmid
22198426
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer Janessa J. Laskin, MD,* Garth Nicholas, MD,† Christopher Lee, MD,‡ Barbara Gitlitz, MD,§ Mark Vincent, MD, Yvon Cormier, MD,¶ Joe Stephenson, MD,# Yee Ung, MD,** Rachel Sanborn, MD,†† Bryn Pressnail, MD,‡‡ Francis Nugent, MD,§§ John Nemunaitis, MD, Martin E. Gleave, MD,¶¶ Nevin Murray, MD,## and Desiree Hao, MD*** decreased serum CLU levels in 95% of patients evaluated. Patients who Purpose: Clusterin (CLU), an antiapoptotic, stress-associated pro- achieved a minimum median CLU level for the population of 38 tein, confers resistance to therapy when overexpressed. This trial g/ml during treatment had a median survival of 27.1 compared with tested custirsen (OGX-011), an inhibitor of CLU protein production, 16.1 months for patients who did not (p  0.02). combined with gemcitabine/platinum in patients with advanced Conclusion: Based on the above results, a randomized phase 3 trial non-small cell lung cancer (NSCLC). to evaluate the survival benefit of custirsen in patients with NSCLC Patients and Methods: This was a single-arm, multicenter, phase is warranted. I/II study in chemotherapy-naive stage IIIB/IV NSCLC. Custirsen

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Mar 1, 2012

References

  • Antisense therapy for cancer
    Gleave
  • Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer
    Zoubeidi
  • Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models
    Miyake
  • Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
    Miyake
  • Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin
    Zellweger
  • Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model
    Zellweger
  • Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo
    July
  • [Relationship of clusterin expression with Bax and p53 expression in non-small cell lung cancer]
    Niu
  • Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry
    Zellweger
  • A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
    Chi
  • Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic
    Miyake
  • Clusterin as a therapeutic target for radiation sensitization in a lung cancer model
    Cao
  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Scher
  • A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
    Chi
  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Schiller
  • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse
  • Randomized Phase II Trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06c
    Saad
  • Gemcitabine-associated thrombotic thrombocytopenic purpura
    Zupancic
  • Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man
    Berman
  • Cisplatin-associated cortical blindness
    Pippitt
  • Cancer statistics, 2009
    Jemal
  • Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state
    Poon
  • Structural characterization of clusterin-chaperone client protein complexes
    Wyatt
  • Clusterin inhibits apoptosis by interacting with activated Bax
    Zhang
  • Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells
    Zoubeidi
  • Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity
    Santilli
  • Correlating structure and stability of DNA duplexes with incorporated 2′-O-modified RNA analogues
    Tereshko
  • Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
    Chi
  • Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group
    Sederholm
  • Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial
    Zatloukal
  • Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer
    Mazzanti
  • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    Scagliotti
  • Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
    Gronberg
  • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    Scagliotti
  • Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
    Rudd
  • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1
    Giaccone
  • Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
    Le Chevalier
  • Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
    Numico